平安好医生(01833.HK)续涨12%屡创上市新高
美国出现首宗武汉肺炎确诊个案,武汉新型冠状病毒感染肺炎已蔓延至最少13省,全国确诊个案已增至440宗,死亡病例增至9宗,美国及澳门也出现首宗确诊个案。
获麦格理升价至78元的平安好医生(01833.HK)连升第六天兼第二天创上市新高,股价承昨天逆大跌市涨逾6%破顶强势,午後升幅扩至12%,报74.9元即市新高,成交已达1,109万股,涉资7.9亿元。
麦格理昨天报告料平安好医生去年下半年收入按年增长18%,若撇除2018年下半年企业采购之影响,按年增长实为41%。该行相信,会员销售将持续带动高毛利网上医疗服务,去年下半年及今年相关业务按年增长可分别达111%及81%,毛利前景亦将持续改善。预计今年收入按年增长将反弹至35%,上调公司2019-2021年每股盈测,料2021年每股盈利0.12元人民币。重申「跑赢大市」,目标价升20%至78元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.